Immunome, Inc. IMNM 深 滬
已收盤 02-06 16:00:00 美东时间
24.88
+0.880
+3.67%
華盛通- 最 高25.76
- 今 開24.61
- 成交量 113.84万股
- 最 低 24.32
- 昨 收 24.00
- 總市值 27.45亿
- 52周最高 27.65
- 市盈率 靜 --
- 換手率 1.03%
- 52周最低 5.1501
- 委 比 99.41%
- 總股本 1.10亿
- 歷史最高 63.78
- 量 比 0.70
- 振 幅 6.00%
- 歷史最低 2.09
- 每 手 1
- 風險率 5.34%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 阿斯麦、美光科技、SanDisk获大行上调目标价；美国银行、富国银行绩后遭多家机构下调目标价
今日重点评级关注：Benchmark：维持TNL Mediagene"投机性买入"评级，目标价从3.5美元升至14美元；康托·菲茨杰拉德：维持Eupraxia Pharmaceuticals"超配"评级，目标价从11美元升至19美元
01-16 10:04
Wedbush Reiterates Outperform on Immunome, Maintains $31 Price Target
Wedbush analyst David Nierengarten reiterates Immunome (NASDAQ:IMNM) with a Outperform and maintains $31 price target.
01-15 22:19
Immunome Announces Follow-On Public Offering Pricing
Immunome ( ($IMNM) ) has issued an update. On December 16, 2025, Immunome annou...
2025-12-18 06:18
美股大行评级 | 潜在涨幅263.64%！Milestone Pharmaceuticals获富国银行升目标价至8美元，维持"超配"评级
今日重点评级关注：富国银行：维持Milestone Pharmaceuticals"超配"评级，目标价从4美元升至8美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从31美元升至33美元
2025-12-17 10:46
Guggenheim Maintains Buy on Immunome, Raises Price Target to $35
Guggenheim analyst Michael Schmidt maintains Immunome (NASDAQ:IMNM) with a Buy and raises the price target from $25 to $35.
2025-12-16 21:48
美股牛股 | KYTX大涨超23%，Miv-cel临床试验取得积极成果；以星航运涨近9%，获瑞士航运集团收购要约
KYTX大涨超23%，Miv-cel临床试验取得积极成果；IMNM涨近16%，实验性药物晚期临床试验达主要终点；以星航运涨近9%，获瑞士航运集团收购要约>>
2025-12-16 19:53
What's Going On With Immunome Shares Monday?
Immunome shares trade higher on Monday after the company announced results from the global pivotal Phase 3 RINGSIDE trial of varegcasetat and met its primary endpoint.
2025-12-16 05:14
Immunome announces proposed public offering
Immunome (NASDAQ:IMNM) announced on Monday its plans to commence an underwritten public offering to issue and sell $400M of shares, and the underwriter will have a 30-day option to purchase up to an a...
2025-12-16 05:07
Immunome Announces $400M Offering
In connection with the proposed offering, Immunome expects to grant the underwriters a 30-day option to purchase up to an additional $60 million of shares of its common stock. There can be no assurance as to whether or
2025-12-16 05:02
Why Is Immunome Stock Soaring Monday?
Immunome stock surges after positive results from Phase 3 trial for desmoid tumors, meeting all key endpoints.
2025-12-16 01:12
